SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Akoya Biosciences, Inc. – ‘10-K’ for 12/31/22 – ‘EX-4.2’

On:  Monday, 3/6/23, at 5:35pm ET   ·   As of:  3/7/23   ·   For:  12/31/22   ·   Accession #:  1558370-23-2954   ·   File #:  1-40344

Previous ‘10-K’:  ‘10-K’ on 3/15/22 for 12/31/21   ·   Next & Latest:  ‘10-K’ on 3/5/24 for 12/31/23   ·   12 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/07/23  Akoya Biosciences, Inc.           10-K       12/31/22  103:14M                                    Toppan Merrill Bridge/FA

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.89M 
 7: EX-4.2      Instrument Defining the Rights of Security Holders  HTML     46K 
 2: EX-10.22    Material Contract                                   HTML   1.35M 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     27K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     34K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     34K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     30K 
13: R1          Document and Entity Information                     HTML     97K 
14: R2          Consolidated Balance Sheets                         HTML    148K 
15: R3          Consolidated Balance Sheets (Parenthetical)         HTML     45K 
16: R4          Consolidated Statements of Operations               HTML    126K 
17: R5          Consolidated Statements of Comprehensive Loss       HTML     51K 
18: R6          Consolidated Statements of Redeemable Convertible   HTML    108K 
                Preferred Stock and Stockholders Equity                          
19: R7          Consolidated Statements of Cash Flows               HTML    138K 
20: R8          The company and basis of presentation               HTML     37K 
21: R9          Summary of significant accounting policies          HTML    106K 
22: R10         Significant risks and uncertainties including       HTML     32K 
                business and credit concentrations                               
23: R11         Fair value of financial instruments                 HTML    178K 
24: R12         Property and equipment, net                         HTML     67K 
25: R13         Intangible assets and goodwill                      HTML     86K 
26: R14         Accrued expenses and other current liabilities      HTML     43K 
27: R15         Debt                                                HTML     59K 
28: R16         Stockholder's equity (Deficit)                      HTML     37K 
29: R17         Stock compensation plans                            HTML    123K 
30: R18         Employee stock purchase plan                        HTML    126K 
31: R19         Income taxes                                        HTML    137K 
32: R20         Commitments and contingencies                       HTML     31K 
33: R21         Net loss per share attributable to common           HTML     57K 
                stockholders                                                     
34: R22         Segments                                            HTML     62K 
35: R23         Related party transactions                          HTML     31K 
36: R24         Leases                                              HTML    141K 
37: R25         Subsequent events                                   HTML     30K 
38: R26         Summary of significant accounting policies          HTML    178K 
                (Policies)                                                       
39: R27         Summary of significant accounting policies          HTML     48K 
                (Tables)                                                         
40: R28         Fair value of financial instruments (Tables)        HTML    183K 
41: R29         Property and equipment, net (Tables)                HTML     67K 
42: R30         Intangible assets and goodwill (Tables)             HTML     87K 
43: R31         Accrued expense and other current liabilities       HTML     42K 
                (Tables)                                                         
44: R32         Debt (Tables)                                       HTML     55K 
45: R33         Stock compensation plans (Tables)                   HTML    123K 
46: R34         Income taxes (Tables)                               HTML    137K 
47: R35         Net loss per share attributable to common           HTML     57K 
                stockholders (Tables)                                            
48: R36         Segments (Tables)                                   HTML     56K 
49: R37         Leases (Tables)                                     HTML    142K 
50: R38         The company and basis of presentation - Initial     HTML     54K 
                public offering (Details)                                        
51: R39         The company and basis of presentation - Liquidity   HTML     38K 
                and going concern (Details)                                      
52: R40         Summary of significant accounting policies -        HTML     30K 
                Accounts receivable (Details)                                    
53: R41         Summary of significant accounting policies -        HTML     33K 
                Intangible assets (Details)                                      
54: R42         Summary of significant accounting policies -        HTML     57K 
                Service and Other Revenue and Disaggregation of                  
                Revenue (Details)                                                
55: R43         Summary of significant accounting policies -        HTML     31K 
                Capitalized software development costs (Details)                 
56: R44         Summary of significant accounting policies -        HTML     30K 
                Advertising expenses (Details)                                   
57: R45         Summary of significant accounting policies -        HTML     35K 
                Deferred offering costs and stock-based                          
                compensation (Details)                                           
58: R46         Significant risks and uncertainties including       HTML     37K 
                business and credit concentrations (Details)                     
59: R47         Fair value of financial instruments (Details)       HTML     60K 
60: R48         Fair value of financial instruments - Cash, cash    HTML     43K 
                equivalents and marketable securities (Details)                  
61: R49         Fair value of financial instruments - Innovatus     HTML     40K 
                Term Loan (Details)                                              
62: R50         Fair value of financial instruments - Recurring     HTML     49K 
                Basis Unobservable (Details)                                     
63: R51         Property and equipment, net (Details)               HTML     54K 
64: R52         Property and equipment, net - Demo inventory        HTML     37K 
                (Details)                                                        
65: R53         Intangible assets and goodwill (Details)            HTML     62K 
66: R54         Intangible assets and goodwill - Amortization       HTML     44K 
                expense related to identifiable intangible assets                
                in future periods (Details)                                      
67: R55         Intangible assets and goodwill - Goodwill balance   HTML     30K 
                (Details)                                                        
68: R56         Accrued expenses and other current liabilities      HTML     39K 
                (Details)                                                        
69: R57         Debt - Term Loan Agreements (Details)               HTML     84K 
70: R58         Debt - Debt components (Details)                    HTML     43K 
71: R59         Debt - Debt maturities (Details)                    HTML     41K 
72: R60         Debt - Sale of Series D Preferred Stock (Details)   HTML     35K 
73: R61         Stockholder's equity (Deficit) (Details)            HTML     53K 
74: R62         Stock compensation plans - 2021 Equity Incentive    HTML     36K 
                Plan (Details)                                                   
75: R63         Stock compensation plans - 2015 Equity Incentive    HTML     38K 
                Plan (Details)                                                   
76: R64         Stock compensation plans - Summary of option        HTML     69K 
                activity (Details)                                               
77: R65         Stock compensation plans - Stock Options (Details)  HTML     50K 
78: R66         Stock compensation plans - Restricted Stock Units   HTML     55K 
                (Details)                                                        
79: R67         Stock compensation plans - Stock-based              HTML     46K 
                compensation expense and unrecognized compensation               
                cost (Details)                                                   
80: R68         Employee stock purchase plan (Details)              HTML     41K 
81: R69         Income taxes (Details)                              HTML     52K 
82: R70         Income taxes - Components of net income (Loss)      HTML     38K 
                Before Income Taxes (Details)                                    
83: R71         Income taxes - Income tax provision (Details)       HTML     51K 
84: R72         Income taxes - Reconciliation between income tax    HTML     52K 
                benefit and expected tax benefit at the statutory                
                rate (Details)                                                   
85: R73         Income taxes - Significant components of net        HTML     64K 
                deferred tax liability (Details)                                 
86: R74         Income taxes - Rollforward of uncertain tax         HTML     34K 
                positions related to research and development tax                
                credits (Details)                                                
87: R75         Commitments and contingencies - License Agreements  HTML     38K 
                (Details)                                                        
88: R76         Net loss per share attributable to common           HTML     66K 
                stockholders (Details)                                           
89: R77         Net loss per share attributable to common           HTML     38K 
                stockholders - Antidilutive shares (Details)                     
90: R78         Segments (Details)                                  HTML     46K 
91: R79         Segments - Revenue (Details)                        HTML     43K 
92: R80         Related party transactions (Details)                HTML     45K 
93: R81         Leases - Adoption of ASU 2016-02 (Details)          HTML    110K 
94: R82         Leases - Office and warehouse leases (Details)      HTML     51K 
95: R83         Leases - Lease cost classification (Details)        HTML     40K 
96: R84         Leases - Future minimum commitments under           HTML     47K 
                operating leases (Details)                                       
97: R85         Leases - Future minimum commitments under           HTML     40K 
                financing leases (Details)                                       
98: R86         Leases - Weighted-average remaining lease term,     HTML     47K 
                incremental borrowing rate, and supplemental cash                
                flow information (Details)                                       
101: XML         IDEA XML File -- Filing Summary                      XML    193K  
99: XML         XBRL Instance -- akya-20221231x10k_htm               XML   2.61M 
100: EXCEL       IDEA Workbook of Financial Reports                  XLSX    187K  
 9: EX-101.CAL  XBRL Calculations -- akya-20221231_cal               XML    245K 
10: EX-101.DEF  XBRL Definitions -- akya-20221231_def                XML    737K 
11: EX-101.LAB  XBRL Labels -- akya-20221231_lab                     XML   1.63M 
12: EX-101.PRE  XBRL Presentations -- akya-20221231_pre              XML   1.25M 
 8: EX-101.SCH  XBRL Schema -- akya-20221231                         XSD    202K 
102: JSON        XBRL Instance as JSON Data -- MetaLinks              547±   868K  
103: ZIP         XBRL Zipped Folder -- 0001558370-23-002954-xbrl      Zip   1.40M  


‘EX-4.2’   —   Instrument Defining the Rights of Security Holders


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:  C:  <!  <> 

Exhibit 4.2

DESCRIPTION OF CAPITAL STOCK

REGISTERED PURSUANT TO SECTION 12

OF THE SECURITIES EXCHANGE ACT OF 1934

The following description of the common stock of Akoya Biosciences, Inc. (“we,” “us” and “our”) is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Certificate of Incorporation (Certificate of Incorporation), our Amended and Restated Bylaws (Bylaws) and our Amended and Restated Investors’ Rights Agreement (“Investors’ Rights Agreement “). This description also summarizes relevant provisions of General Corporation Law of the State of Delaware (the “DGCL”). We encourage you to read these materials for additional information.

General

Our authorized capital stock consists of 500,000,000 shares of common stock, $0.00001 par value per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock are undesignated.

Common Stock

The holders of our common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. The holders of our common stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our board of directors out of funds legally available, subject to preferences that may be applicable to preferred stock, if any, then outstanding. In the event of a liquidation, dissolution or winding up of our company, the holders of common stock will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. Our common stock has no preemptive or conversion rights or other subscription rights or redemption or sinking fund provisions.

Preferred Stock

Our Certificate of Incorporation authorizes our board of directors to establish one or more series of preferred stock (including convertible preferred stock). Unless required by law or any stock exchange, the authorized shares of preferred stock will be available for issuance without further action by the holders of our common stock. Our board of directors will be able to determine, with respect to any series of preferred stock, the powers (including voting powers), preferences and relative, participating, optional or other special rights, and the qualifications, limitations, or restrictions thereof. No shares of preferred stock have been issued or are outstanding as of the date of the filing of the Annual Report on Form 10-K of which this Description forms a part, and we have no present plan to issue any shares of preferred stock.

Anti-Takeover Matters in our Governing Documents and Under Delaware Law

Our Certificate of Incorporation and our Bylaws contain, and the DGCL contains, provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile or abusive change of control, and enhance the ability of our board of directors to maximize stockholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an antitakeover effect and may delay, deter, or prevent a merger or acquisition by means of a tender offer, a proxy contest, or other takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares of common stock held by stockholders.

Authorized But Unissued Capital Stock

The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more


difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger, or otherwise.

Classified Board of Directors

Our Certificate of Incorporation provides that our board of directors be divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. Directors may only be removed from our board of directors for cause by the affirmative vote of at least 662∕3% of the voting power of all of our then-outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class. In addition, our Certificate of Incorporation provides that, subject to the rights granted to one or more series of preferred stock then outstanding, any newly created directorship on the board of directors that results from an increase in the number of directors and any vacancies on our board of directors will be filled only by the affirmative vote of a majority of the remaining directors, even if less than a quorum, or by a sole remaining director. A director chosen to fill a position resulting from an increase in the number of directors will hold office until the next election of the director’s class and until the director’s successor is duly elected and qualified, or until the director’s earlier death, resignation or removal. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of us or changes in our management.

Delaware Anti-Takeover Law

We are subject to Section 203 of the DGCL, which is an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date that the person became an interested stockholder, unless the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Generally, a business combination includes a merger, asset or stock sale, or another transaction resulting in a financial benefit to the interested stockholder. Generally, an interested stockholder is a person who, together with affiliates and associates, owns 15% or more of the corporation’s outstanding voting stock or is the corporation’s affiliate or associate and was the owner of 15% or more of the corporation’s outstanding voting stock at any time within the three-year period immediately before the date of determination. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our board, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by stockholders.

No Cumulative Voting

Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. Our Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our stock entitled to vote generally in the election of directors are able to elect all of our directors.

Special Stockholder Meetings

Our Certificate of Incorporation provides that special meetings of our stockholders may be called at any time only by or at the direction of the board of directors, the chair of the board of directors or our Chief Executive Officer. Our Bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management.

Director Nominations and Stockholder Proposals

Our Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder’s notice must be received at our principal executive offices not less than


90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. Our Bylaws also specify requirements as to the form and content of a stockholder’s notice. Our Bylaws allow the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to influence or obtain control.

Stockholder Action by Written Consent

Pursuant to Section 228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice, and without a vote if a consent or consents in writing, setting forth the action so taken, is or are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless the certificate of incorporation provides otherwise. Our Certificate of Incorporation precludes stockholder action by written consent.

Amendment of Certificate of Incorporation or Bylaws

The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation’s certificate of incorporation or bylaws, unless a corporation’s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our Bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 662∕3% of the votes which all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 662∕3% of the votes which all our stockholders would be entitled to cast in any election of directors will be required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our Certificate of Incorporation described above.

The foregoing provisions of our Certificate of Incorporation and our Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares of common stock that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management or delaying or preventing a transaction that might benefit you or other minority stockholders.

Exclusive Forum

Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware be the sole and exclusive forum for: (1) any derivative action or proceeding brought on behalf of our company, (2) any action asserting a claim of breach of fiduciary duty owed by any director, officer, agent, or other employee or stockholder of our company to us or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (4) any action asserting a claim governed by the internal affairs doctrine, in each case subject to such Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. It will further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolutions of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the “Securities Act”). The exclusive forum clauses described above shall not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended or any other claim for which the federal courts have exclusive jurisdiction. Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of


discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable in such action. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our Certificate of Incorporation.

Limitations of Liability and Indemnification

The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors’ fiduciary duties, subject to certain exceptions. Our Certificate of Incorporation includes a provision that eliminates the personal liability of directors for monetary damages to the corporation or its stockholders for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL. The effect of these provisions is to eliminate the rights of us and our stockholders, through stockholders’ derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation does not apply to any breaches of the director’s duty of loyalty, any acts or omissions not in good faith or that involve intentional misconduct or knowing violation of law, any authorization of dividends or stock redemptions or repurchases paid or made in violation of the DGCL, or for any transaction from which the director derived an improper personal benefit.

Our Bylaws generally rovide that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the DGCL. We also are expressly authorized to carry directors’ and officers’ liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers.

The limitation of liability, indemnification and advancement provisions in our Certificate of Incorporation and our Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought.

We have entered into indemnification agreements with each of our directors and executive officers. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC such indemnification is against public policy and is therefore unenforceable.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent’s address is 6201 15th Avenue Brooklyn, New York 11219.

Listing

Our common stock is listed on Nasdaq under the symbol “AKYA.”



5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/14/24  Akoya Biosciences, Inc.           10-Q        3/31/24   95:8.6M                                   Toppan Merrill Bridge/FA
 3/05/24  Akoya Biosciences, Inc.           10-K       12/31/23  106:12M                                    Toppan Merrill Bridge/FA
 3/05/24  Akoya Biosciences, Inc.           S-8         3/05/24    4:74K                                    Toppan Merrill/FA
 6/09/23  Akoya Biosciences, Inc.           424B5                  1:541K                                   Toppan Merrill/FA
 6/07/23  Akoya Biosciences, Inc.           424B5                  1:541K                                   Toppan Merrill/FA


7 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/07/22  Akoya Biosciences, Inc.           S-3                    7:2.2M                                   Toppan Merrill/FA
 8/09/22  Akoya Biosciences, Inc.           10-Q        6/30/22   91:10M                                    Toppan Merrill Bridge/FA
 6/02/22  Akoya Biosciences, Inc.           8-K:1,2,9   6/01/22   11:1.2M                                   Toppan Merrill/FA
 3/29/22  Akoya Biosciences, Inc.           8-K:1,9     3/23/22   11:280K                                   Toppan Merrill/FA
 3/15/22  Akoya Biosciences, Inc.           10-K       12/31/21   92:10M                                    Toppan Merrill Bridge/FA
 4/12/21  Akoya Biosciences, Inc.           S-1/A                  8:6.1M                                   Toppan Merrill/FA
 3/26/21  Akoya Biosciences, Inc.           S-1                   21:8M                                     Toppan Merrill/FA
Top
Filing Submission 0001558370-23-002954   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 12:14:34.2pm ET